Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211877 | 0.87 | CA1 (0.51) | EGFRHIF1APOLB | |
| SCHEMBL16211732 | 0.87 | EPHX2 (0.51) | MAPTGAASMN1; SMN2VNN1LMNA | |
| SCHEMBL18464053 | 0.85 | MEN1 (0.55) | MAPTGAAEGFRSMN1; SMN2LMNA | |
| SCHEMBL20237137 | 0.85 | RAB9A (0.49) | EGFRMAPK1HIF1A | |
| SCHEMBL17618052 | 0.84 | EGFR (0.53) | MAPTEGFRSMN1; SMN2LMNAKMT2A | |
| SCHEMBL30024522 | 0.84 | HIF1A (0.59) | MAPTEGFRSMN1; SMN2LMNAKMT2A | |
| SCHEMBL18423980 | 0.84 | HIF1A (0.59) | MAPTEGFRSMN1; SMN2LMNAKMT2A | |
| SCHEMBL20236937 | 0.83 | EGFR (0.52) | MAPTEGFRSMN1; SMN2LMNAKMT2A | |
| SCHEMBL16211444 | 0.83 | EGFR (0.52) | MAPTGAAEGFRSMN1; SMN2KMT2A | |
| SCHEMBL15761767 | 0.83 | NTRK1 (0.59) | MAPTGAASMN1; SMN2VNN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571426-B2 | Compositions for preventing or treating lupus | CHONG KUN DANG PHARMACEUTICAL CORP. | 2023-02-07 | — | — | US | disclosed |
| US-11571426-B2 | Compositions for preventing or treating lupus | CHONG KUN DANG PHARMACEUTICAL CORP. | 2023-02-07 | — | — | US | disclosed |
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-03-18 | — | — | US | disclosed |
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-03-18 | — | — | US | disclosed |
| EP-3755336-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | Chong Kun Dang Pharmaceutical Corp. (KR) | 2020-12-30 | — | — | EP | disclosed |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-11-26 | — | — | US | disclosed |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-11-26 | — | — | US | disclosed |
| CN-111801101-A | Composition for preventing or treating uveitis | 株式会社钟根堂 | 2020-10-20 | — | — | CN | disclosed |
| EP-3713578-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | Chong Kun Dang Pharmaceutical Corp. (KR) | 2020-09-30 | — | — | EP | disclosed |
| CN-111372589-A | Composition for preventing or treating lupus | 株式会社钟根堂 | 2020-07-03 | — | — | CN | disclosed |
| WO-2019103524-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2019-05-31 | — | — | WO | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| EP-2991982-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | UACA, PDE6C, PDE6H | MAPT 402/4885GAA 3043/4885EGFR 4794/4885 |
| US-11571426-B2 | Compositions for preventing or treating lupus | SSB, TLR9, TLR5 | MAPT 3853/4885GAA 1620/4885EGFR 4681/4885 |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | MAPT 92/4885GAA 330/4885EGFR 3867/4885 |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | MAPT 92/4885GAA 330/4885EGFR 3867/4885 |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | SSB, TLR9, TLR5 | MAPT 3853/4885GAA 1620/4885EGFR 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.